Explore BrainMass

Explore BrainMass

    Vertex Merger Article Synopsis

    This content was COPIED from BrainMass.com - View the original, and get the already-completed solution here!

    Please provide a synopsis of the article in the link below. The synopsis needs to focus on the goal of the corporate restructuring that Vertex was involved in and your general thought's on the dealing with Eli-Lily.

    http://www.prnewswire.com/news-releases/vertex-pharmaceuticals-restructures-agreement-with-eli-lilly-vertex-to-lead-development-of-novel-oral-hepatitis-c-protease-inhibitor-vx-950-73647862.html

    © BrainMass Inc. brainmass.com June 4, 2020, 1:53 am ad1c9bdddf
    https://brainmass.com/business/mergers-and-acquisitions/vertex-merger-article-synopsis-425975

    Solution Preview

    Please see the attached file(s) for the complete tutorial.

    Vertex Merger Synopsis

    Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in its restructured agreement with Eli-Lily is now solely responsible of developing and commercializing VX-950, an oral hepatitis C viral protease inhibitor. The restructuring was a result of Eli-Lily's reprioritizing its research portfolio and Vertex's focus on specialty pharmaceutical markets and desire to retain greater downstream rights on its own compounds.

    As a result of the ...

    Solution Summary

    The solution provides a synopsis that focuses on the goal of the corporate restructuring that Vertex was involved in.

    $2.19

    ADVERTISEMENT